Data as of Dec 04
| -0.22 / -2.94%|
Starpharma Holdings Ltd. engages in the development of dendrimer products for pharmaceutical, life science and other applications. Dendrimers are synthetic nanoscale polymer that is regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its lead product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Melbourne, Australia.
|Jacinth K. Fairley||CEO, Executive Director & Media Relations Contact|
|Nigel J. Baade||Chief Financial Officer|
|David J. Owen||Vice President-Research|
|Bernard P. Rogers||Secretary, Head-Investor & Media Relations|
|C. Paul Barrett||Vice President-Business Development|